Westfield Capital Management Co. LP trimmed its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 21.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 182,179 shares of the medical research company’s stock after selling 48,963 shares during the quarter. Westfield Capital Management Co. LP owned about 0.37% of Charles River Laboratories Intl. worth $25,851,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. boosted its stake in Charles River Laboratories Intl. by 1.3% during the 1st quarter. BlackRock Inc. now owns 4,587,801 shares of the medical research company’s stock valued at $666,379,000 after purchasing an additional 57,789 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Charles River Laboratories Intl. by 18.0% during the first quarter. AQR Capital Management LLC now owns 2,082,761 shares of the medical research company’s stock valued at $301,042,000 after buying an additional 317,001 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Charles River Laboratories Intl. by 49.4% during the second quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock valued at $138,804,000 after buying an additional 323,625 shares during the last quarter. TimesSquare Capital Management LLC increased its holdings in Charles River Laboratories Intl. by 5.1% in the 2nd quarter. TimesSquare Capital Management LLC now owns 907,850 shares of the medical research company’s stock worth $128,824,000 after buying an additional 44,275 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in Charles River Laboratories Intl. by 6.8% in the 2nd quarter. Fisher Asset Management LLC now owns 471,341 shares of the medical research company’s stock worth $66,883,000 after buying an additional 29,980 shares in the last quarter. 94.40% of the stock is currently owned by institutional investors.

CRL has been the topic of several recent research reports. Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday. Leerink Swann began coverage on Charles River Laboratories Intl. in a report on Monday, June 10th. They set an “outperform” rating for the company. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Svb Leerink initiated coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They issued an “outperform” rating and a $155.00 price target for the company. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and an average target price of $147.62.

NYSE CRL traded up $0.48 on Wednesday, reaching $130.16. The company had a trading volume of 11,224 shares, compared to its average volume of 233,653. The company has a quick ratio of 1.38, a current ratio of 1.59 and a debt-to-equity ratio of 1.47. The stock has a market capitalization of $6.35 billion, a PE ratio of 21.59, a price-to-earnings-growth ratio of 1.66 and a beta of 1.09. The firm’s 50 day moving average price is $132.09 and its 200 day moving average price is $136.35. Charles River Laboratories Intl. Inc has a 12 month low of $103.00 and a 12 month high of $149.07.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.55 by $0.08. The business had revenue of $657.60 million during the quarter, compared to the consensus estimate of $662.61 million. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The business’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.62 EPS. On average, research analysts expect that Charles River Laboratories Intl. Inc will post 6.52 EPS for the current year.

In related news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $130.36, for a total value of $162,819.64. Following the sale, the insider now directly owns 19,327 shares in the company, valued at $2,519,467.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.80% of the stock is currently owned by insiders.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: What is the market perform rating?

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.